부산대학교 도서관

Keywords: ITP; SARS-CoV; vaccines EN ITP SARS-CoV vaccines 703 705 3 11/30/21 20211201 NES 211201 Severe coronavirus disease 2019 (COVID-19), due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), may be associated with mild thrombocytopenia,1,2 and some COVID-19-induced immune thrombocytopenia (ITP) cases have been reported.3,4 Some reports suggest that patients with pre-existing ITP may experience a relapse5 in the case of SARS-CoV-2 infection that could be prevented by vaccination. Interestingly, all ITP relapses occurred within the week after vaccination, as previously described for thrombocytopenia in patients with no pre-existing ITP6 and in a recent series,8 and in two out of three patients after the second dose. Furthermore, the proportion of patients who received non-RNA-based vaccines in our present study was too low (nine patients) to draw any definite conclusion on the safety of non-replicating adenovirus-based vaccines in patients with ITP. [Extracted from the article]